NCT05318872 (ENDOSWIR-VADS) is a clinical trial of ENDOSWIR in Head and Neck Neoplasms, sponsored by University Hospital, Grenoble.

Who is sponsoring NCT05318872?

NCT05318872 is sponsored by University Hospital, Grenoble.

What drugs are being tested in NCT05318872?

Interventions in NCT05318872: ENDOSWIR.

What condition does NCT05318872 study?

NCT05318872 studies Head and Neck Neoplasms.

Is NCT05318872 still recruiting?

NCT05318872 is currently status unknown. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT05318872: ENDOSWIR-VADS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Evaluation of ENDOSWIR Device Versus Pathology for Squamous Cell Carcinoma of Upper Aerodigestive Tract (ENDOSWIR-VADS)

Status unknown Last updated 12 April 2022

What this trial tests

trial testing ENDOSWIR in Head and Neck Neoplasms in 10 participants. Status unknown.

Timeline

11 April 2022

Primary endpoint
30 September 2022

30 June 2023

Quick facts

Lead sponsor	University Hospital, Grenoble
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	10
Start date	11 April 2022
Primary completion	30 September 2022
Estimated completion	30 June 2023

Drugs / interventions tested

ENDOSWIR

Conditions studied

Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A new medical optical device named ENDOSWIR is tested to determine its ability to determine if tissues are cancer or normal tissue on ex-vivo condition for specimen of ENT squamous cell cancers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Head and Neck Neoplasms

Currently open trials in the same condition.

NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting

Other University Hospital, Grenoble trials

Trials by the same sponsor.

NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05318872 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05318872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing